Autolus Therapeutics (AUTL) Projected to Post Quarterly Earnings on Thursday

Key Points

• Autolus will report Q1 2026 results before the market opens on May 14, 2026; analysts expect ($0.29) EPS and about $26.27 million in revenue, with a conference call at 8:30 AM ET.
• In the prior quarter the company reported ($0.34) EPS, missing estimates by $0.07 while revenue was $24.29M, and it currently exhibits very negative profitability metrics (negative ROE and net margin) with analysts forecasting roughly ($1) EPS for the fiscal year.
• Shares trade around $1.70 with a market cap of ~$452.4M, institutional investors hold about 72.8% of the stock, and analysts' consensus is a "Moderate Buy" with an average target of $8.50.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $26.2660 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The firm had revenue of $24.29 million for the quarter, compared to analysts' expectations of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $1.70 on Thursday. The stock's 50-day moving average is $1.50 and its two-hundred day moving average is $1.51. The firm has a market cap of $452.44 million, a price-to-earnings ratio of -1.57 and a beta of 1.93. Autolus Therapeutics has a 1 year low of $1.15 and a 1 year high of $2.70.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Autolus Therapeutics by 29.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 49,864 shares of the company's stock worth $99,000 after buying an additional 11,445 shares during the last quarter. OpenArc Corporate Advisory LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $169,000. Public Employees Retirement System of Ohio purchased a new position in shares of Autolus Therapeutics during the third quarter worth about $216,000. Aquatic Capital Management LLC purchased a new position in shares of Autolus Therapeutics during the third quarter worth about $171,000. Finally, Two Sigma Investments LP grew its holdings in shares of Autolus Therapeutics by 17.3% during the third quarter. Two Sigma Investments LP now owns 172,143 shares of the company's stock worth $281,000 after buying an additional 25,346 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

Analyst Upgrades and Downgrades

AUTL has been the topic of several research reports. Zacks Research raised Autolus Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, March 13th. Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday, April 20th. HC Wainwright initiated coverage on Autolus Therapeutics in a report on Tuesday, February 17th. They set a "buy" rating and a $9.00 price objective on the stock. Mizuho dropped their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 31st. Finally, Weiss Ratings raised Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, April 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $8.50.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.